Mutations in human prothrombin that generate a stable form of meizothrombin or meizothrombin(desF1) cause dysprothrombinemia in both the homozygous and heterozygous state, suggesting that meizothrombin has dominant anticoagulant effects in vivo. The enzymatic characterization of recombinant mouse meizothrombin, meizothrombin(desF1), and thrombin indicates that all three enzymes have similar activity toward the chromogenic substrate S-2238, that meizothrombin and meizothrombin(desF1) have <10% of the fibrinogen clotting activity of thrombin, and that meizothrombin is more active than thrombin or meizothrombin(desF1) for thrombomodulin-dependent protein C activation. Thus, activated mouse prothrombin R157A/R268A is similar to human meizothrombin in activity toward S-2238, fibrinogen, and protein C. The time-to-occlusion after FeCl 3 induced carotid artery injury was delayed (11.8 ± 3.6 min, n = 5) in Cf2+/-mice infused with prothrombin R157A/R268A compared to control mice infused with wild-type prothrombin (5.3 ± 1.5 min, n = 3, P = 0.006). In this model, prothrombin R157A/R268A has anticoagulant activity that reflects its decreased fibrinogen clotting activity and preserved protein C activating activity, and is consistent with dominant inhibition of fibrinogen clotting.
Introduction
Prothrombin is a blood clotting factor that, when activated, generates thrombin, a protease with multiple biological functions. Thrombin clots fibrinogen and activates platelets, and it participates in the feedback regulation of several other procoagulant and anticoagulant enzyme pathways. For example, thrombin binds to thrombomodulin on endothelial cell surfaces, and the thrombin-thrombomodulin complex efficiently activates the serine protease zymogen protein C. Activated protein C cleaves blood clotting factors Va and VIIIa, thereby inhibiting further thrombin generation. The anticoagulant protein C pathway limits intravascular coagulation associated with sepsis and inflammatory responses to endotoxin, 1 and defects in the protein C pathway are common causes of venous thrombosis. 2 During prothrombin activation, at least three active species that may have distinct substrate specificity are produced by selected proteolytic cleavages ( Fig. 1 ). Meizothrombin is generated by the cleavage of the Arg 320 -Thr 321 bond of prothrombin by factor Xa. 3, 4 Meizothrombin(desF1) is generated by autoproteolysis of meizothrombin at Arg 155 -Ser 156 , which removes the membrane binding Gla domain and kringle 1. Thrombin is produced by a second factor Xa cleavage at Arg 271 -Thr 272 . 5, 6 Compared to thrombin, the ability of meizothrombin and meizothrombin(desF1) to clot fibrinogen or activate platelets is markedly reduced. However, both meizothrombin and meizothrombin(desF1) can bind thrombomodulin and activate protein C; in this reaction meizothrombin(desF1) is approximately as active as thrombin, and human meizothrombin appears to be 6-fold more potent than thrombin. [6] [7] [8] Thus, meizothrombin and meizothrombin(desF1) have the potential to function as anticoagulants in vivo by selectively activating the protein C pathway. This possibility is supported by the properties of prothrombin Dhahran (Arg271His), which can be activated by factor Xa to generate a stable form of To assess the anticoagulant potential of meizothrombin, we have prepared and characterized recombinant mouse prothrombin R157A/R268A (aaII) and compared it to wild type prothrombin having Arg residues at these positions (rrII). Prothrombin R157A/R268A (aaII)
was activated to yield a meizothrombin-like species (aaMZa) that was converted slowly to a stable meizothrombin(desF1)-like product (aaMZdesF1a). As observed for the corresponding bovine and human prothrombin derivatives, aaMZa and aaMZdesF1a had markedly reduced ability to clot fibrinogen or activate platelets, but preserved ability to activate protein C. The effects of mouse aaII in vivo were assessed in a model of acute carotid artery thrombosis. S-2238 hydrolysis. The enzyme activity was measured as described above except without inhibitors. Briefly, 150 µl of 1 nM purified enzyme was added to 150 µl of amidolytic buffer containing various concentrations of S-2238, absorbance at 405 nm was determined at 11 sec intervals, and the initial rate of product formation was calculated.
Fibrinogen clotting assay.
A sample of 50 µl of 50 mg/ml bovine fibrinogen (Sigma, St Louis, MO) was added to 0.2 ml fibrinogen clotting buffer (150 mM NaCl, 10 mM imidazole, pH 7.4, 10 mM CaCl 2 , and 6.6 g/L of PEG-6000) containing approximately 2 pmol of protease at 37°C and the clotting time was determined with a fibrometer (BBL fibro system).
Protein C activation. The protein C activation assay was done as previously described with slight modifications.
14 Briefly, CV-1(18A) cells that express human thrombomodulin were harvested, washed twice and resuspended in assay buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM CaCl 2 ). Then 1.5 pmol of protease was added to 98.5 µl of assay buffer containing 10 6 cells and 5 µg of human recombinant protein C. The reaction mixture was incubated at 37°C
for 30 min and the reaction was stopped by the addition of 7.5 µl of assay buffer containing
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From heparin (1 unit/µl), 0.32 µg/µl of antithrombin, and 680 nM hirudin. The samples were centrifuged for 5 min at 15,000 rpm, and 10 µl of supernatant was added to 290 µl of 100 µM pyroGlu-Pro-Arg-p-nitroanilide (S-2366) in 50 mM Tris, pH 8.6, and 50 mM CsCl in microtiter plates and absorbance at 405 nm was determined as a function of time. The concentration of activated protein C was calculated based on standard curve generated using human activated protein C (Haematologic Technologies). The assay was also performed with 32 µg/ml of soluble rabbit thrombomodulin (Haematologic Technologies).
Animals, injury, and monitoring of blood flow. Prothrombin null mice 15 were backcrossed into the 129Svev background for at least 12 generations. Two to four month old heterozygous Cf2+/-male mice were anesthetized by intraperitoneal injection of 70 mg/kg of sodium pentobarbital. A coded sample of recombinant rrII or aaII in 150 µl of TBS was infused in a blinded manner through the tail vein prior to surgery. The carotid artery was isolated and a small animal blood flow meter (Transonic Systems Inc.) was applied. The carotid artery was injured as previously described 16 with slight modification. A filter paper (1 mm x 2 mm) soaked with 10% FeCl 3 solution was applied to the artery for 3 min and the cavity was filled with saline immediately. 16 The flow rate was monitored and recorded and the time-to-occlusion was determined. The injured arteries were excised and fixed in 40% formaldehyde for morphological studies. All the animal experiments and care were done based on the (Fig. 2) . The autolysis of aaMZa to aaMZdesF1a continued over several days (data not shown). These products may be generated by slow cleavage after Arg 149 or possibly Lys 162 , residues that are not present in human prothrombin.
No further processing of aaMZdesF1a to thrombin was observed. Thus, recombinant mutant aaII generates a relatively stable meizothrombin-like product that is susceptible to slow autocatalytic cleavage at sites near Arg 157 .
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The concentrations of aaMZa, aaMZdesF1a, and thrombin were determined by active site titration with PPACK and kinetic constants for S-2238 cleavage were determined by an initial rate method. All three proteases had similar amidolytic activity, with similar values for K m and k cat (Table 1 ). In contrast, the fibrinogen clotting activities of aaMZa and aaMZdesF1a were 5.8 ± 0.6% and 8.4 ± 1.4% that of wild type thrombin, respectively. These results are consistent with the selective loss of activity toward fibrinogen reported previously for human and bovine meizothrombin and meizothrombin(desF1). 6, 8 Products of aaII activation are potent thrombomodulin dependent protein C activators. The ability of aaMZa and aaMZdesF1a to activate protein C was assessed with membrane-bound thrombomodulin (Fig. 3) . CV-1(18A) cells 14 express full-length human thrombomodulin on the cell surface. In the presence of CV-1(18A) cells, protein C was rapidly activated by either aaMZa or aaMZdesF1a. Recombinant aaMZa was approximately two-fold more active than an equal concentration of aaMZdesF1a or mouse thrombin. The control cell line
IdE5 expresses a form of human thrombomodulin that lacks the 5 th EGF domain and cannot bind thrombin, 14 and IdE5 cells did not support protein C activation by these proteases (Fig. 3) .
Soluble rabbit thrombomodulin also stimulated protein C activation by mouse aaMZa, aaMZdesF1a, or thrombin with approximately equal efficacy, and the reaction was dependent on calcium ions (data not shown). Therefore, the aaMZa and aaMZdesF1a species derived from aaII selectively activate the protein C anticoagulant pathway, and aaMZa was more efficient than aaMZdesF1 or thrombin when thrombomodulin was presented on a membrane surface. These properties are similar to those of aaMZa and aaMZdesF1a derived from a similar mutant human prothrombin. The effects of rrII and aaII on carotid artery thrombosis were compared in a model of ferric chloride-induced acute injury (Fig. 5 ). Mice injected with rrII had total arterial occlusion after 5.3 ± 1.5 min (Table 2 ). Mice injected with aaII had a substantially longer time to occlusion of 11.8 ± 3.6 min (P = 0.006). The thrombi consisted of layers of platelets, fibrin and red blood cells (Fig. 5B) , and the morphology did not differ between the mice injected with rrII and aaII.
The antithrombotic effect of aaII was dose dependent with a maximal increase in the time to occlusion at doses of 50 µg and 100 µg, suggesting that aaII has a dominant inhibitory effect in vivo. The time to occlusion after injection of 25 µg aaII was significantly shorter than the time to occlusion after injection of 50 µg (P < 0.01). Increasing the dose to 100 µg did not further increase the time to occlusion compared a dose of 50 µg.
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Discussion
Thrombin generation usually proceeds through the intermediate MZa, 4 which has potent anticoagulant activity in vitro. Compared to thrombin, MZa of either human or bovine origin has greatly reduced activity toward fibrinogen or platelets, but increased ability to bind thrombomodulin and activate protein C on cell surfaces. [6] [7] [8] Furthermore, kringle 2 of MZa shields the heparin binding site on the thrombin B chain, 17 so that MZa is resistant to inhibition by antithrombin and heparin. 3, 6, 8 Our studies indicate that the properties of mouse aaMZa and aaMZdesF1a are similar to those reported previously for the corresponding bovine and human proteins, suggesting that their functions are shared among mammals. The biological importance of regulating MZa, and also MZdesF1a, is supported by the conservation of the cleavage sites needed to convert them to thrombin in more distantly related vertebrates such as chicken and hagfish. 18 The anticoagulant properties of MZa and MZdesF1a may increase the threshold for the full blood clotting response by promoting sustained protein C activation when the rate of thrombin generation is relatively low. By the same mechanism, stable versions of these prothrombin activation intermediates could have antithrombotic activity in vivo, although this possibility has not been assessed previously. A mutant prothrombin also might competitively interfere with the activation of wild type prothrombin, thereby inhibiting intravascular coagulation by an additional mechanism. In the present study, recombinant mouse aaII delayed carotid artery thrombosis in an acute injury model (Fig. 5) , confirming the predicted antithrombotic properties of MZa. In addition, these results suggest that a similar variant of human prothrombin could have therapeutic utility in settings where the increased activation of protein C may be beneficial.
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Patients with bacterial sepsis often have acquired protein C deficiency, and mortality correlates inversely with protein C levels. 19, 20 A recent study also showed that heterozygous deficiency of protein C in mice was associated with increased mortality after challenge with bacterial endotoxin. 21 These effects suggest that the anticoagulant and anti-inflammatory properties of activated protein C are beneficial in sepsis, but can be limited by depletion of endogenous protein C. This deficiency can be bypassed by the intravenous administration of activated protein C, which is reported to improve survival and reduce the coagulopathic changes associated with bacterial sepsis in animal models 22 and in human clinical trials. 23 However, activated protein C also increases the incidence of serious bleeding. 23 Bleeding caused by exogenous activated protein C might be circumvented by increasing the activation of endogenous protein C. For example, an anticoagulant human prothrombin similar to aaII would generate stable MZa and activate protein C mainly at local sites of ongoing blood coagulation where it may be most effective, possibly with reduced systemic effects. 1 The plasma half-life of prothrombin is 3 days, so that one dose of anticoagulant prothrombin may produce a therapeutic effect similar to that of a typical 3 day continuous infusion of activated protein C. 23 The amount of prothrombin required may not be prohibitive. For example, 4 mg prothrombin per kilogram body weight would double the plasma prothrombin concentraton ( 1.5 µM), and this amount of protein is comparable to the total infusion of 2.3 mg activated protein C per kilogram body weight during a course of treatment for septic shock. However, the interactions among protein C pathway components are complex, 1 and further studies will be required to address the therapeutic potential of anticoagulant prothrombins. 
